Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Santaris makes executive appointments

This article was originally published in Scrip

Executive Summary

Denmark-based Santaris Pharma has expanded its executive team, appointing Dr Mark Wedel vice-president and chief medical officer and Stuart Mackey vice-president of strategy and chief business officer. Dr Wedel, who will be responsible for global clinical development programmes and therapeutic portfolio management, joins from Isis Pharmaceuticals, where he was senior vice-president of drug development and chief medical officer. Mr Mackey spent the last 10 years at Amgen, where he most recently served as managing director of Amgen Ventures. They will be responsible for driving global business development for Santaris's proprietary RNA-targeted Locked Nucleic Acid drug platform. Both executives will be located at the company's recently established US subsidiary in San Diego, California.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts